AstraZeneca's Brilinta gets into the FDA's fast lane for new use

AstraZeneca's ($AZN) clot-fighter Brilinta got a lift from the FDA Wednesday, as the agency said it would fast-track review of the drug for broader use. The drugmaker could get an OK in the third quarter, for use in heart attack patients up to three years after the event. Release